Meeting
2021 ASCO Annual Meeting
AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer.
Authors
Aditya Bardia
Massachusetts General Hospital Cancer Center, Boston, MA
Aditya Bardia , Javier Cortes , Sara A. Hurvitz , Suzette Delaloge , Hiroji Iwata , Shao Zhimin , Dheepak Kanagavel , Patrick Cohen , Qianying Liu , Sylvaine Cartot-Cotton , Vasiliki Pelekanou , Joyce O'Shaughnessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT04478266
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS1104)
DOI
10.1200/JCO.2021.39.15_suppl.TPS1104
Abstract #
TPS1104
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
First Author: Richard S. Finn
Poster
2023 ASCO Annual Meeting
Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.
First Author: Takahiro Kogawa
Poster
2019 ASCO Annual Meeting
EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator’s choice (IC) of endocrine therapy (ET) for ER+/HER2- advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy.
First Author: Aditya Bardia
Poster
2023 ASCO Annual Meeting
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
First Author: Charles Geyer